KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Alnylam Pharmaceuticals (ALNY) over the last 14 years, with Sep 2025 value amounting to 20.76%.

  • Alnylam Pharmaceuticals' EBITDA Margin rose 4107.00% to 20.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.76%, marking a year-over-year increase of 1726.00%. This contributed to the annual value of -12.87% for FY2024, which is 1005.00% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its EBITDA Margin stood at 20.76% for Q3 2025, which was up 373.53% from -7.59% recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' EBITDA Margin peaked at 20.76% during Q3 2025, and registered a low of -201.59% during Q1 2025.
  • Moreover, its 3-year median value for EBITDA Margin was -15.76% (2024), whereas its average is -35.46%.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' EBITDA Margin spiked by 17,449bps in 2023, and later tumbled by 18,752bps in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' EBITDA Margin (Quarterly) stood at -99.60% in 2021, then skyrocketed by 3,740bps to -62.19% in 2022, then spiked by 3,288bps to -29.32% in 2023, then surged by 1,356bps to -15.76% in 2024, then spiked by 4,107bps to 20.76% in 2025.
  • Its last three reported values are 20.76% in Q3 2025, -7.59% for Q2 2025, and -201.59% during Q1 2025.